Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yee AJ, Raje NS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	denosumab breast cancer prostate cancer bone loss Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e634a06fd60f46699b3fc6394d02c27f
record_format	dspace
spelling	oai:doaj.org-article:e634a06fd60f46699b3fc6394d02c27f2021-12-02T06:36:04ZDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients1178-1998https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f2012-09-01T00:00:00Zhttps://www.dovepress.com/denosumab-a-rank-ligand-inhibitor-for-the-management-of-bone-loss-in-c-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer.Keywords: denosumab, zoledronic acid, bone loss, breast cancer, prostate cancerYee AJRaje NSDove Medical Pressarticledenosumab breast cancer prostate cancer bone lossGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 331-338 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	denosumab breast cancer prostate cancer bone loss Geriatrics RC952-954.6
spellingShingle	denosumab breast cancer prostate cancer bone loss Geriatrics RC952-954.6 Yee AJ Raje NS Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
description	Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer.Keywords: denosumab, zoledronic acid, bone loss, breast cancer, prostate cancer
format	article
author	Yee AJ Raje NS
author_facet	Yee AJ Raje NS
author_sort	Yee AJ
title	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
title_short	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
title_full	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
title_fullStr	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
title_full_unstemmed	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
title_sort	denosumab, a rank ligand inhibitor, for the management of bone loss in cancer patients
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f
work_keys_str_mv	AT yeeaj denosumabarankligandinhibitorforthemanagementofbonelossincancerpatients AT rajens denosumabarankligandinhibitorforthemanagementofbonelossincancerpatients
_version_	1718399844386603008

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Ejemplares similares